ArticleDrug safety2005
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Article in Drug safety, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Drug-drug interaction software in clinical practice: a systematic review.European journal of clinical pharmacology · 2015Pooled it
- Rhabdomyolysis associated withFrontiers in pharmacology · 2026Article
- Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.Clinical pharmacokinetics · 2024Article
- Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia.Iranian journal of public health · 2023Article
- Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case.JMIR medical informatics · 2021Article
- Categorization and association analysis of risk factors for adverse drug events.European journal of clinical pharmacology · 2018Review
- Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017Article
- Statin drug-drug interactions in a Romanian community pharmacy.Clujul medical (1957) · 2016Article
- A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.Lipids in health and disease · 2015Article
- Evaluation of potential drug - drug interactions in general medicine ward of teaching hospital in southern India.Journal of clinical and diagnostic research : JCDR · 2015Article
- Potential drug interactions with statins: Estonian register-based study.Open medicine (Warsaw, Poland) · 2015Article
- Treatment of cholesterol in the elderly: statins and beyond.Current atherosclerosis reports · 2014Review
- Potential statin-drug interactions: prevalence and clinical significance.SpringerPlus · 2014Article
- Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.PloS one · 2013Article
- Niacin: another look at an underutilized lipid-lowering medication.Nature reviews. Endocrinology · 2012Review
- Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.European journal of clinical pharmacology · 2012Article
- Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital.The Australasian medical journal · 2011Article
- Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil.Clinics (Sao Paulo, Brazil) · 2011Article
- Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.British journal of pharmacology · 2010Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-drug interactions (DDIs) are a well known risk factor for adverse drug reactions. HMG-CoA reductase inhibitors ('statins') are a cornerstone in the treatment of dyslipidaemia and patients with dyslipidaemia are concomitantly treated with a variety of additional drugs. Since DDIs are associated with adverse reactions, we performed a cross-sectional study to assess the prevalence of potentially critical drug-drug and drug-statin interactions in an outpatient adult population with dyslipidaemia.
methodsData from patients with dyslipidaemia treated with a statin were collected from 242 practitioners from different parts of Switzerland. The medication list was screened for potentially harmful DDIs with statins or other drugs using an interactive electronic drug interaction program.
resultsWe included 2742 ambulatory statin-treated patients (mean age +/- SD 65.1 +/- 11.1 years; 61.6% males) with (mean +/- SD) 3.2 +/- 1.6 diagnoses and 4.9 +/- 2.4 drugs prescribed. Of those, 190 patients (6.9%) had a total of 198 potentially harmful drug-statin interactions. Interacting drugs were fibrates or nicotinic acid (9.5% of patients with drug-statin interactions), cytochrome P450 (CYP) 3A4 inhibitors (70.5%), digoxin (22.6%) or ciclosporin (cyclosporine) [1.6%]. The proportion of patients with a potential drug-statin interaction was 12.1% for simvastatin, 10.0% for atorvastatin, 3.8% for fluvastatin and 0.3% for pravastatin. Additionally, the program identified 393 potentially critical non-statin DDIs in 288 patients.
conclusionsCYP3A4 inhibitors are the most frequent cause of potential drug interactions with statins. As the risk for developing rhabdomyolysis is increased in patients with drug-statin interactions, clinicians should be aware of the most frequently observed drug-statin interactions and how these interactions can be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.